Literature DB >> 17072103

Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine.

Toru Kobayashi1, Kazuo Washiyama, Kazutaka Ikeda.   

Abstract

Paroxetine is commonly used as a selective serotonin reuptake inhibitor for the treatment of depression and other psychiatric disorders. However, the molecular mechanisms of the paroxetine effects have not yet been sufficiently clarified. Using Xenopus oocyte expression assays, we investigated the effects of paroxetine on G protein-activated inwardly rectifying K+ (GIRK) channels, which play an important role in reducing neuronal excitability in most brain regions and the heart rate. In oocytes injected with mRNAs for GIRK1/GIRK2, GIRK2, or GIRK1/GIRK4 subunits, paroxetine reversibly reduced inward currents through the expressed GIRK channels. The inhibition was concentration-dependent, but voltage-independent and time-independent during each voltage pulse. However, two structurally different antidepressants: milnacipran and trazodone, caused only a small inhibition of basal GIRK currents. Additionally, Kir1.1 and Kir2.1 channels were insensitive to all of the antidepressants. Furthermore, the GIRK currents induced by activation of A1 adenosine receptors or by ethanol were inhibited by extracellularly applied paroxetine in a concentration-dependent manner, but not affected by intracellularly applied paroxetine. Our results suggest that inhibition of GIRK channels by paroxetine may contribute partly to some of its therapeutic effects and adverse side effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072103     DOI: 10.1254/jphs.fp0060708

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  13 in total

1.  Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

2.  Evaluation of the pharmacological involvement of ATP-sensitive potassium (KATP) channels in the antidepressant-like effects of topiramate on mice.

Authors:  Saeed Shakiba; Mehdi Rezaee; Khashayar Afshari; Kiarash Kazemi; Khadijeh-Alsadat Sharifi; Nazgol-Sadat Haddadi; Arvin Haj-Mirzaian; Aida Kamalian; Seyedeh Zarifeh Jazaeri; Kent Richter; Ahmad Reza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-03-04       Impact factor: 3.000

3.  Uncontrollable, but not controllable, stress desensitizes 5-HT1A receptors in the dorsal raphe nucleus.

Authors:  Robert R Rozeske; Andrew K Evans; Matthew G Frank; Linda R Watkins; Christopher A Lowry; Steven F Maier
Journal:  J Neurosci       Date:  2011-10-05       Impact factor: 6.167

4.  GABA transporter lysine 448: a key residue for tricyclic antidepressants interaction.

Authors:  Francesca Cherubino; Andreea Miszner; Maria Daniela Renna; Rachele Sangaletti; Stefano Giovannardi; Elena Bossi
Journal:  Cell Mol Life Sci       Date:  2009-12       Impact factor: 9.261

5.  Paroxetine suppresses recombinant human P2X7 responses.

Authors:  Phuong Dao-Ung; Kristen K Skarratt; Stephen J Fuller; Leanne Stokes
Journal:  Purinergic Signal       Date:  2015-09-05       Impact factor: 3.765

Review 6.  Advances in Targeting GIRK Channels in Disease.

Authors:  Yulin Zhao; Isabel Gameiro-Ros; Ian W Glaaser; Paul A Slesinger
Journal:  Trends Pharmacol Sci       Date:  2021-01-16       Impact factor: 14.819

7.  Identification of selective agonists and antagonists to g protein-activated inwardly rectifying potassium channels: candidate medicines for drug dependence and pain.

Authors:  D Nishizawa; N Gajya; K Ikeda
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

8.  The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice.

Authors:  Y Takamatsu; H Yamamoto; Y Hagino; A Markou; K Ikeda
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

9.  Inhibition of g protein-activated inwardly rectifying k channels by phencyclidine.

Authors:  Toru Kobayashi; Daisuke Nishizawa; Kazutaka Ikeda
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

10.  Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.